“We’re Going to Pray From God That This Does Work”: Trump Keeps Promoting Unproven Drugs

The cocktail carries significant risks and may not fight the coronavirus.

Tasos Katopodis/Getty

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

On Saturday afternoon, President Trump again used the platform of a White House coronavirus briefing to push two unproven drugs as a treatment, feeding into a swirl of medical misinformation and increasing the distance between his ad-hoc views and those of his scientist advisers.

When asked about the anti-malaria drug chloroquine as a possible coronavirus cure, Trump said it, along with the antibiotic azithromycin, could work and suggested they would be shared widely with patients.

“It’s going to be distributed. I think New York is getting 10,000 units,” he said. “We’re going to find out. As the expression goes, ‘What do we have to lose?'”

Trump promoted the drugs at Friday’s briefing and earlier on Saturday morning on Twitter, despite the fact that the Food and Drug Administration has not approved either drug to treat COVID-19, the disease caused by coronavirus. There’s good reason for that. Despite some positive reports stemming from studies with small samples, the untested drug cocktail carries significant risks. As I reported this morning:

When used in conjunction with other medication or in the wrong dosage, taking them can be devastating. In China, officials recommended the use of chloroquine in February after some promising trials, but after a researchers in Wuhan discovered that doubling a daily dose of the drug could lead to death, China quickly “cautioned doctors and health officials about the drug’s lethal side effects and rolled back its usage,” Bloomberg reported. The AFP wire service has reported that social media messages pushing chloroquine have circulated widely in Nigeria, and that health officials there have seen cases of poisoning from the drug. 

Trump seemed unconcerned with these inconvenient details. “This would be a gift from heaven, this would be a gift from God if it works,” he said. “So we’re going to pray from God that it does work.”

When pressed by a reporter about the wisdom of Trump pushing an unverified solution, Vice President Mike Pence said, “There is some anecdotal evidence that several existing medicines may have brought relief to patients struggling in China and Europe.” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, used that same word—”anecdotal”—to describe the case for a prescription that Trump, only hours prior to briefing, insisted should be “put in use IMMEDIATELY.” 

“The president is talking about hope for people and it’s not an unreasonable thing to hope for people,” Fauci said. “My job as a scientist is to ultimately prove without a doubt that a drug is not only safe but works.”

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate